Navigation Links
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:2/25/2008

ting timelines, and safety of the Company's products and technologies. Any statement describing the Company's expectations or beliefs is a forward- looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward- looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them". Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise,


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , October 30, 2014 Investor-Edge ... Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... Synthetic Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,549.23, down 0.33%, the Dow Jones Industrial Average ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada has ... detects CYP2C19 genetic mutations in less than 60 minutes ... CYP2C19 System is the first near-patient DNA test for ... to the system’s ease of use, Health Canada has ... such as doctors, nurses, pharmacists, and laboratory technicians, in ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Society, an,international association focused on endocrinological research and,practice, today ... ENDO 08, the annual conference of the Society, which ... over 14,000 members from 80,countries, many of whom attend ... research and clinical care., The purpose of today,s ...
... industry, academia, government and health providers draws dozens of ... ... June 16 The unique connectivity, talent and,collaboration that has ... in recent years will be on show at BIO 2008 ...
... today announced,the appointment of Jim Meade, Ph.D., ... addition to contributing to the strategic direction ... for managing the development of,Lentigen,s partnerships, stakeholder ... and other key aspects of,corporate development., ...
Cached Biology Technology:'Breakthroughs Ahead,' Endocrine Society Tells Security Analysts 2Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub 2Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub 3Lentigen Appoints Jim Meade as Vice President of Corporate Development 2
(Date:10/30/2014)... October 30, 2014 – Bacteria in the gastrointestinal ... for digestion. Yet, these same bacteria can induce ... they penetrate the gut and enter the bloodstream. ... to protect the body, chronic or systemic inflammation ... research has established the involvement of inflammatory processes ...
(Date:10/30/2014)... | Heidelberg, 30 October 2014 Biological membranes are ... understanding of adsorption of solution ions onto lipid ... Now, a new study provides a quantitative description ... solution ions. Joanna Kotyńska and Zbigniew Figaszewski from ... of a study describing these findings, just published ...
(Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
Breaking Biology News(10 mins):Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... stage is set for the local fauna! ,Computer scientists ... birdsong archives of Berlin,s Humboldt University, have developed a kind ... with entertainment, but a lot to do with the protection ... reliably recognise the characteristic birdsong of different species of birds, ...
... drop to dangerously low levels in diseases such as ... critical cells, doctors filter platelets from donated blood, but ... infections and cause other side effects in patients who ... scientists have been trying to generate platelets from embryonic ...
... on opposite sides of a canyon have evolved to cope ... or cell membranes. Scientists have found that bacteria change these ... looking at the appearance of the bacteria as well as ... August issue of Microbiology , will start a new ...
Cached Biology News:Birdsong not just for the birds 2Bacteria reveal secret of adaptation at Evolution Canyon 2
... Agencourt offers pre-validated ... over 1500 amplicons within ... serine/threonin kinases, and more ... These assays were ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... Mouse anti-Yersinia pestis F1 antigen, ... Applications: ELISA: Use at ... at an assay dependent dilution. WB: ... Predicted molecular weight: 18 kDa. Not ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
Biology Products: